Answers are grounded in this paper and cite their sources.
Systematic review compares infection rates in BCMA and GPRC5D therapies for multiple myeloma, suggesting significant differences in infection risk.
e19511 Background: The approved B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted bispecific antibodies (BsAbs) have demonstrated efficacy in relapsed/refractory multiple myeloma. However, infectious complications remain a major concern, and comparative class-level infection data remain incomplete. Methods: We searched PubMed/MEDLINE, EMBASE, and Scopus from inception through January 10, 2026, using predefined eligibility criteria to include clinical trials only of approved BsAbs (teclistamab, elranatamab, linvoseltamab, and talquetamab). Arm-level safety data were grouped by target class and regimen (monotherapy or combination). Monotherapy arms were pooled using random-effects meta-analysis of proportions. Endpoints were infections (any-grade, grade ≥3, opportunistic) and infection-related deaths. Heterogeneity was assessed using I² and τ². Indirect class comparisons used arm-level random-effects meta-regression on the logit scale. PROSPERO ID CRD420261288395. Results: Ten monotherapy arms were included (BCMA k=5, n=500; GPRC5D k=5, n=375). Any-grade infections were higher in BCMA monotherapy, showing 74.3% (95% CI 70.2–77.9; I²=0%) vs 62.1% (50.5–72.5; I²=57.7%) for GPRC5D. Grade ≥3 infections were 41.0% (32.3–50.4; I²=71.5%) vs 23.5% (14.1–36.6; I²=73.7%), respectively. Infection-related deaths were 8.6% (6.1–11.8; I²=22.9%) vs 2.0% (0.9–4.0; I²=0.0%), representing a 4-fold higher pooled estimate. Opportunistic infections were reported in 8 monotherapy arms (BCMA k=3; GPRC5D k=5); GPRC5D pooled incidence was 5.0% (3.2–7.9; I²=0%), whereas BCMA was summarized descriptively (9.1–11.1%). In arm-level meta-regression, GPRC5D was associated with lower odds of any-grade infections (β=−0.531, p=0.0038), grade ≥3 infections (β=−0.798, p=0.0248), opportunistic infections (β=−0.783, p=0.0092), and infection-related deaths (β=−1.526, p=0.00064). Exploratory analysis of combination-regimen arms (n=540) showed high infection rates, with any-grade infections of 84.5% (68.1–93.3; I²=89.5%), grade ≥3 infections of 41.8% (27.4–57.8; I²=87.4%), and infection-related deaths of 6.0% (3.3–10.5; I²=47.3%). Given the limited number of arms and substantial heterogeneity, these estimates should be interpreted as descriptive. Conclusions: Infections were frequent with severe and fatal events. Across pooled monotherapy estimates and arm-level meta-regression, BCMA vs GPRC5D-directed therapy showed higher infection burden. Separation was most consistent for infection-related deaths, while grade ≥3 infections showed greater heterogeneity. Despite heterogeneity, cross-trial limitations, and incomplete opportunistic infection reporting, these findings reinforce the need for careful monitoring and optimized supportive care and prophylaxis during treatment.
No takes yet. Share an insight, caveat, or question.
Pleitez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: